The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic therapies and Bain is funding a growing CDMO.
The deal is another example of a surge in acquisitions of private biotech assets at a time when public company buyouts have become more sparse. Organon is betting its commercial reach will spur sales ...
Some results have been hidden because they may be inaccessible to you